[Therapy of polycythemia vera with myleran].


By NIEL WALD, TAKASHI HOSHINO AND MARY E. SEARS MYLERAN#{176} was developed in the course of a study of the tumor-inhibiting effect of various sulfonic acid esters by Haddow and Timmis.1 Because of the neutropenia, unaccompanied by other side effects, which was observed during its ineffective clinical trial in vaniotis types of cancer in man, Myieran was… (More)


2 Figures and Tables

Slides referencing similar topics